Aytu BioPharma, Inc. (AYTU)
$1.99+1.02%Close
SELLRECOVERY · day 18
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $16M
- Beta
- 0.27
- P/E (TTM)
- -1.45
- Short % float
- 4.54%
- Days to cover
- 4.7
- SI change
- +10.8%
- 1W
- -2.93%
- 1M
- -0.50%
- vs SPY 1W
- -2.79%
- vs SPY 1M
- -3.01%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 39
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-31.7%
REV YoY-
ROE-0.0%
EPS YoY-
ROA-13.6%
GROSS64
OP-14
NET-25
[VALUATION]
P/E TTM-1.45
P/E FWD-
SECTOR PE20.34
INDUSTRY PE19.31
P/B0.69
P/FCF-
EV/EBITDA-1.55
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E51.33
ALTMAN Z-
CURR RATIO1.13
ND/EBITDA-
BETA0.27
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on AYTU?
- LOPJLB’s latest quantitative signal on Aytu BioPharma, Inc. (AYTU) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is AYTU in?
- Aytu BioPharma, Inc. (AYTU) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Aytu BioPharma, Inc. (AYTU) do?
- Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailore…